Market Overview

Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata

Share:

Topline Phase 2a Data from the 4 mg and 8 mg Cohorts Expected in
Fourth Quarter of 2018

Concert
Pharmaceuticals, Inc.
(NASDAQ:CNCE) today announced that it has
completed patient enrollment of its Phase 2a trial evaluating CTP-543
for the treatment of moderate-to-severe alopecia areata. The Company
expects to report topline data from the 4 mg and 8 mg cohorts of the
Phase 2a trial in the fourth quarter of 2018. Additionally, a Phase 2b
clinical trial is expected to begin in 2019.

"The speed with which we enrolled the trial speaks to the significant
unmet need for alopecia areata and interest in this program. We are
grateful to the patients who volunteered to participate in our trial,"
stated James Cassella, Ph.D., Chief Development Officer of Concert
Pharmaceuticals.

The Phase 2a trial is a double-blind, randomized, placebo-controlled,
sequential dose trial to evaluate the safety and efficacy of CTP-543 in
adult patients with moderate-to-severe alopecia areata. Approximately 90
patients were randomized to receive one of two doses of CTP-543 (4 mg or
8 mg twice daily) or placebo. The primary outcome measure will utilize
the severity of alopecia tool (SALT) after 24 weeks of dosing. If
appropriate, the protocol may be amended to explore 12 mg twice daily of
CTP-543. Additional information about the trial is available on www.clinicaltrials.gov.

About CTP-543 and Alopecia Areata

CTP-543 was discovered by applying Concert's deuterium chemistry
technology to modify ruxolitinib, a drug which selectively inhibits
Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available
under the name Jakafi® in the United States for the treatment of certain
blood disorders. Ruxolitinib has been used to treat alopecia areata in
academic settings, including an investigator-sponsored clinical trial,
and has been reported to promote hair growth in individuals with
moderate-to-severe disease. Deuterium modification of ruxolitinib was
found to alter its human pharmacokinetics in ways which may enhance its
use as a treatment for alopecia areata. The U.S. Food and Drug
Administration (FDA) has granted Fast Track designation for CTP-543.

Alopecia areata is an autoimmune disease that results in partial or
complete loss of hair on the scalp and body that may affect up to
650,000 Americans at any given time1. The scalp is the most
commonly affected area, but any hair-bearing site can be affected alone
or together with the scalp. Onset of the disease can occur throughout
life and affects both women and men. Alopecia areata can be associated
with serious psychological consequences, including anxiety and
depression. There are currently no drugs approved by the U.S. Food and
Drug Administration (FDA) for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that
it focused on under its Patient-Focused Drug Development Initiative
(PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient
perspectives into an earlier stage of product development. Following the
U.S. Food and Drug Administration's (FDA) Patient-Focused Drug
Development meeting held in September 2017 on alopecia areata, the FDA
summarized the input shared by patients and patient representatives in a Voice
of the Patient
report. Additional information on the PFDDI is
available online.

About Concert

Concert
Pharmaceuticals
is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform®
(deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with starts with previously studied compounds, including
approved drugs, in which deuterium substitution has the potential to
enhance clinical safety, tolerability or efficacy. Concert has a broad
pipeline
 of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders. For
more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations,
plans and prospects, including statements about our expectations on the
clinical development of CTP-543, and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including: the uncertainties
inherent in the initiation of future clinical trials, whether
preliminary results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical trials
will be indicative of the results of later clinical trials, expectations
for regulatory approvals and other factors discussed in the "Risk
Factors" section of our most recent Annual Report on Form 10-K filed
with the Securities and Exchange Commission and in other filings that we
make with the Securities and Exchange Commission. In addition, any
forward-looking statements included in this press release represent our
views only as of the date of this release and should not be relied upon
as representing our views as of any subsequent date. We specifically
disclaim any obligation to update any forward-looking statements
included in this press release.

1 Fricke M. Epidemiology and Burden of alopecia areata: a
systemic review. Clinical, Cosmetic and Investigational Dermatology.
2015; Vol 8. 397-403.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
Jakafi®
is a registered trademark of Incyte Corporation.

View Comments and Join the Discussion!